Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (November 2025)

44 slides from Day One Biopharmaceuticals's investor presentation, Nov 24, 2025

  1. Slide 1: Day One Biopharmaceuticals: Targeted therapies for people of all ages

    Slide 1: Day One Biopharmaceuticals: Targeted therapies for people of all ages

    Exhibit 99.2 Day One Biopharmaceuticals Targeted therapies for people of all ages November 2025

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases 3

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner Who we are • Commercial-stage biopharmaceutical company • Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible • Focused on advancing first- or best-in-class medicines for childhood and

  5. Slide 5: Near-term opportunities are the foundation for long-term growth and sustainability

    Slide 5: Near-term opportunities are the foundation for long-term growth and sustainability

    Compelling near-term opportunities to help patients are the foundation for long-term growth and sustainability Day One’s Future Potential Value creation Pillars to Support Growth • Continued revenue growth from OJEMDA globally Accomplishments • Indication expansion in front-line pLGG with FIREFLY-2

  6. Slide 6: Our pipeline

    Slide 6: Our pipeline

    Our pipeline Our goal is to take aim at the gaps that have left patients and their families behind. Phase 1 Phase 1 Product Therapeutic Phase 3/ Recent & Anticipated Dose Dose Phase 2 Approved Candidate Area Registrational Milestones Escalation Optimization FDA accelerated approval Tovorafenib April

  7. Slide 7: OJEMDA: Relapsed or refractory BRAF-altered pLGG

    Slide 7: OJEMDA: Relapsed or refractory BRAF-altered pLGG

    OJEMDA Relapsed or refractory BRAF-altered pLGG Nora Living with pLGG 7

  8. Slide 8: Pediatric low-grade glioma: the most common type of brain tumor in children

    Slide 8: Pediatric low-grade glioma: the most common type of brain tumor in children

    Pediatric low-grade glioma: The most common type of brain tumor in children A serious and life-threatening disease • For the majority of patients with pLGG in the relapsed setting, there is no standard of care, and until recently, no approved therapies pLGGs are chronic and • Up to 75% of pLGGs have

  9. Slide 9: OJEMDA overview and U.S. prescribing information

    Slide 9: OJEMDA overview and U.S. prescribing information

    Overview U.S. prescribing information for OJEMDA Available in tablet formulation and pediatric- friendly powder for oral suspension Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF

  10. Slide 10: Product profile aligns with what physicians are looking for

    Slide 10: Product profile aligns with what physicians are looking for

    Product profile aligns with what physicians are looking for in a therapy • Meaningful tumor stabilization or shrinkage may be possible with OJEMDA, in the clinical trial: Efficacy • 51% of children experienced tumor shrinkage by at least 25% • 82% of children saw their tumors shrink or remain stable

  11. Slide 11: Foundational U.S. opportunity for OJEMDA in relapsed and frontline pLGG

    Slide 11: Foundational U.S. opportunity for OJEMDA in relapsed and frontline pLGG

    Foundational U.S. opportunity for OJEMDA in both relapsed and frontline pLGG § Incident Therapeutic Build for New Illustrative pLGG Patient Flow Prevalence of Systemically-Treated Patients Under 25 Years ~26,000 pLGG Patients to be Treated in Frontline Setting Frontline (1L) Relapsed / Refractory (2

  12. Slide 12: Delivering double-digit Q3 2025 growth across core metrics

    Slide 12: Delivering double-digit Q3 2025 growth across core metrics

    Delivering double-digit Q3 2025 growth across core metrics 15% 18% 19% Growth in Growth in Growth in 1 Net Product Revenue Total Prescriptions New Patient Starts $38.5M in Q3 2025 1,256 TRx in Q3 2025 1 12 Prescriptions are approximations based on data available as of September 30, 2025. Quarterly g

  13. Slide 13: Commercial execution driving strong top-line growth

    Slide 13: Commercial execution driving strong top-line growth

    Commercial execution +$4.9M +15% driving strong top-line growth and performance $38.5 ~89% $33.6 Compounded Achieved $38.5M in 1,2 Annual Growth $30.5 Q3 2025 OJEMDA net product revenue Net Revenue Highlights • Achieved $102.6M in net product revenue for 2025 year-to-date • Year-to-date net product

  14. Slide 14: Accelerating uptake driving TRx growth

    Slide 14: Accelerating uptake driving TRx growth

    Accelerating uptake OJEMDA 1 +18% Prescriptions (TRx) driving TRx growth and demonstrating 1,256 durable demand ~97% 1,062 Compounded 2 19% growth in new Annual Growth 923 patient starts driven by 3 2-year follow up data Prescription Highlights • Gaining share in the 2L setting as prescriber confide

  15. Slide 15: Positive physician experience continues to build

    Slide 15: Positive physician experience continues to build

    Positive physician experience continues to build across treatment settings 2L Adoption Increasing Strong Persistency 2L adoption grew >60% in 20 months median duration of treatment for 1 past 12 months EAP patients Increasing number of HCPs stating OJEMDA 75% of EAP patients who reached 24 months is

  16. Slide 16: Prescriber confidence driving repeat use

    Slide 16: Prescriber confidence driving repeat use

    Prescriber confidence driving repeat use with significant opportunity remaining Breadth & Depth of Prescribing by Account Breadth & Depth Highlights • >60% of prescribing accounts have 1 Patient treated multiple patients with OJEMDA • 28% sequential growth in number of 1 accounts with 4 or more pati

  17. Slide 17: Focused execution driving continued adoption through 2025

    Slide 17: Focused execution driving continued adoption through 2025

    Focused execution and meaningful progress driving continued adoption and treatment durability through 2025 D R I V E NEW PAT I ENT S TA RT S O P T IM IZ E P E RS IS T E N C E Support physicians and patients Increase depth of prescribing Continue to expand to optimize their experience on by expanding

  18. Slide 18: Strengthening the OJEMDA story through data generation

    Slide 18: Strengthening the OJEMDA story through data generation

    We continue to strengthen the OJEMDA story through enhancing the target product profile and data generation FIREFLY-1 3-Year Data Highlighting clinical stability following Establishing treatment with OJEMDA and opportunity for OJEMDA as the retreatment Standard of Care in 2L r/r BRAF- Potential to f

  19. Slide 19: Intellectual property and regulatory designations

    Slide 19: Intellectual property and regulatory designations

    Intellectual Property OJEMDA IP • Composition of matter patent of tovorafenib provides protection in summary and 1 the U.S. out to mid-2036 (with patent term extension) regulatory • Patent portfolio covers formulations, manufacturing methods, and uses of tovorafenib, with issued and pending applicat

  20. Slide 20: 3-year follow-up data from the FIREFLY-1 trial

    Slide 20: 3-year follow-up data from the FIREFLY-1 trial

    3-year follow- up data from the FIREFLY-1 trial studying OJEMDA Phase 2 FIREFLY-1 Trial 20

  21. Slide 21: After OJEMDA cycles, patients could enter an observation period

    Slide 21: After OJEMDA cycles, patients could enter an observation period

    After 26 OJEMDA cycles, patients could enter an observation period* Updated 3-year analysis † Time to next treatment, n=76 Subsequent anticancer therapy ‡ Treatment-free interval, n=39 or death Observation period OJEMDA Arm 1, n=77 Day 1 (no anticancer therapy) 26 cycles* (~24 months) Received 26 cy

  22. Slide 22: Deep, durable responses with OJEMDA

    Slide 22: Deep, durable responses with OJEMDA

    Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO Updated 3-year analysis 3-year Exposure * Arm 1 (n=76) Completed ≥26 cycles of treatment, n (%) 44/76 (58) Response (IRC) † ORR, n (%) 40 (53) Best Overall Response, n (%) CR 0 PR 30 (39) MR 10 (13) ‡ SD 22 (29) PD 13 (17) NE 1 (1)

  23. Slide 23: Many patients continued OJEMDA beyond radiographic progression

    Slide 23: Many patients continued OJEMDA beyond radiographic progression

    Many patients continued OJEMDA beyond RAPNO-defined radiographic progression by IRC Updated 3-year analysis † In the 3-year follow-up analysis, 38 patients had RAPNO-defined PD while on OJEMDA 100% 75% OJEMDA ‡ Reduced tumor size 50% beyond PD: at last scan prior to 100% (38/38) last dose, relative

  24. Slide 24: RAPNO PFS and time to next treatment

    Slide 24: RAPNO PFS and time to next treatment

    RAPNO PFS demonstrates efficacy with OJEMDA; time to next treatment more accurately reflects the full clinical benefit Updated 3-year analysis § Median time to next treatment was 42.6 months (95% CI 36.7–NE) • RAPNO defines radiographic PD 1.0 as a ≥25% increase in tumor size ₸ from nadir —not basel

  25. Slide 25: Tumor rebound was minimal in first months off therapy

    Slide 25: Tumor rebound was minimal in first months off therapy

    Tumor rebound was minimal in the first 6 months off therapy Updated 3-year analysis 80 No tumor rebound (n=27) Tumor rebound (n=12)* Post-treatment 60 observation patients, n=39 40 3 months 6 months † † post-EOT post-EOT 20 Median time between prior scan 1.8 (0–4.2) and last dose, months (range) 0 ‡

  26. Slide 26: Early evidence of retreatment activity

    Slide 26: Early evidence of retreatment activity

    Early evidence of retreatment activity observed in the OJEMDA-retreated cohort Updated 3-year analysis Patients retreated with OJEMDA n=8 At time of data cutoff: • All 8 patients receiving OJEMDA -38.3 Median change, % (range)* (-80.9–0) retreatment were still on therapy † • Median tumor size was sm

  27. Slide 27: Treatment-free interval

    Slide 27: Treatment-free interval

    77% of 39 patients were treatment free for at least 12 months; median treatment-free interval not yet reached Updated 3-year analysis 100 90 Post-treatment observation † patients n=39 80 70 Median duration of treatment, months (range) 24.6 (16.0–38.7) 60 50 Treatment free Median follow-up from last

  28. Slide 28: No new safety signals in the 3-year update

    Slide 28: No new safety signals in the 3-year update

    No new safety signals were observed in the 3-year update Updated 3-year analysis Safety analysis set Safety analysis set Preferred term* (n=137) (n=137), n (%) Grade ≥3 TRAEs, n (%) Any 91 (66) All TEAEs 137 (100) Decreased growth velocity 46 (34) All TRAEs 136 (99) Anemia 19 (14) Grade ≥3 TEAEs 113

  29. Slide 29: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG

    Slide 29: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG

    FIREFLY-2 Pivotal Phase 3 trial of tovorafenib in front-line pLGG Bradon Living with pLGG since age 11 29

  30. Slide 30: Front-line expansion opportunity for tovorafenib in pLGG

    Slide 30: Front-line expansion opportunity for tovorafenib in pLGG

    Expansion into front-line treatment represents a meaningful expansion opportunity for tovorafenib in pLGG Trial design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RAPNO-LGG criteria, assessed by vs SoC chemotherapy blinded

  31. Slide 31: Emi-Le: B7-H4-targeted ADC

    Slide 31: Emi-Le: B7-H4-targeted ADC

    Emi-Le B7-H4-targeted antibody-drug conjugate (ADC) 31

  32. Slide 32: Emi-Le: opportunity to address unmet need in adenoid cystic carcinoma

    Slide 32: Emi-Le: opportunity to address unmet need in adenoid cystic carcinoma

    Emi-Le Represents A Transformational Opportunity To Address The 6 Unmet Need For Patients With Adenoid Cystic Carcinoma (ACC) 2 • ACC is a rare cancer, with an annual US incidence of ~1,300 patients • Recurrent/metastatic ACC often presents with aggressive features; no 2 approved therapeutic options

  33. Slide 33: DAY301: PTK7-targeted ADC

    Slide 33: DAY301: PTK7-targeted ADC

    DAY301 PTK7-targeted antibody-drug conjugate (ADC) 33

  34. Slide 34: DAY301: Next generation ADC targeting PTK7

    Slide 34: DAY301: Next generation ADC targeting PTK7

    DAY301: Next generation ADC targeting PTK7 Substantial development PTK7: clinically- DAY301: potential first- and commercial potential validated ADC target in-class asset for DAY301 Anti-tumor activity of anti-PTK7 Novel ADC active in High PTK7 expression in ADC demonstrated in Phase 1b preclinical

  35. Slide 35: PTK7: A clinically-validated ADC target

    Slide 35: PTK7: A clinically-validated ADC target

    PTK7: A clinically-validated ADC target Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index 1 • Clinical results for cofetuzumab pelidotin demonstrated proof of concept for PTK7-targeted ADCs • Cofetuzumab pelidotin activity seen in multiple tumor types: • Ovarian (P

  36. Slide 36: DAY301: Potential first-in-class asset

    Slide 36: DAY301: Potential first-in-class asset

    DAY301: Potential first-in-class asset DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs • Tumor regression at tolerable doses seen in multiple preclinical models • Higher HNSTD in cyno toxicology studies; payload with known safety profile • High cell

  37. Slide 37: DAY301: Improved tumor regression vs. benchmarks in preclinical models

    Slide 37: DAY301: Improved tumor regression vs. benchmarks in preclinical models

    DAY301: First-in-class potential Improved tumor regression activity demonstrated for DAY301 vs. benchmarks in multiple preclinical models 4,000 PDX 362797 SCLC PDX 362310 TNBC PDX LD1-200615 HNSCC 5,000 2,400 H-score 120 H-score 210 H-score 255 3,000 4,000 2,000 1,600 3,000 2,000 1,200 2,000 800 1,0

  38. Slide 38: DAY301: Development and commercial opportunities

    Slide 38: DAY301: Development and commercial opportunities

    DAY301: Encouraging development and commercial opportunities PTK7 U.S. Patient Population ORR at Median OS at Indication Expression (>1+) Cases/Deaths Relapse Relapse 2 3 7 7 Endometrial 100% 67,880/13,250 39% 9 months 1 3 4 4 Esophageal SCC 76% 22,370/16,130 5% 3 months 2 3 14 15 Gastric 35% 26,890

  39. Slide 39: DAY301: Initial Phase 1a/b clinical trial design

    Slide 39: DAY301: Initial Phase 1a/b clinical trial design

    DAY301: Initial Phase1a/b clinical trial design Key design elements Adult & pediatric development • BOIN design for efficiency of dose escalation • Potential adult indications include platinum resistant ovarian cancer, squamous NSCLC, esophageal SCC, HNSCC, endometrial, and/or SCLC • Backfill active

  40. Slide 40: Summary

    Slide 40: Summary

    Summary 40

  41. Slide 41: Third quarter 2025 financial results

    Slide 41: Third quarter 2025 financial results

    Third quarter 2025 financial results Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Financial Summary 9/30/25 9/30/24 9/30/25 9/30/24 ($ in millions) OJEMDA Net Revenue 38.5 20.1 102.6 28.3 License Revenue 1.3 73.7 1.9 73.7 Total Revenue $39.8 $93.8 $104.5 $102.0 Cost of P

  42. Slide 42: Day One is well positioned for sustainable growth and long-term success

    Slide 42: Day One is well positioned for sustainable growth and long-term success

    Day One is well positioned for sustainable growth and long-term success Execute on clinical Drive OJEMDA development pipeline for revenue growth FIREFLY-2 and DAY301 Leverage our development and Maintain strong capital commercialization expertise to position while investing in further expand our mul

  43. Slide 43: Appendix

    Slide 43: Appendix

    Appendix 43

  44. Slide 44: Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations

    Slide 44: Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations

    Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations MAPK RAS-independent activation of the Tovorafenib is an investigational, oral, pathway MAPK pathway selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase RAS • Activity in tum

Source: SEC EDGAR · 8-K filed Nov 24, 2025

More decks from Day One Biopharmaceuticals Inc